Christina Elisabeth Herder
Amministratore Delegato presso IDOGEN AB (PUBL)
Posizioni attive di Christina Elisabeth Herder
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| IDOGEN AB (PUBL) | Direttore/Membro del Consiglio | 01/01/2017 | - |
| Amministratore Delegato | 01/09/2022 | - | |
| Contatto Relazioni con gli Investitori | 01/01/2017 | - | |
| Independent Dir/Board Member | 01/01/2017 | 01/09/2022 | |
| ELICERA THERAPEUTICS AB | Direttore/Membro del Consiglio | 01/01/2020 | - |
| Independent Dir/Board Member | 01/01/2020 | - | |
| Herder Consulting AB | Direttore/Membro del Consiglio | - | - |
| Glycovisc BioTech AB | Corporate Officer/Principal | - | - |
| Medivir Personal AB | Corporate Officer/Principal | - | - |
Storia della carriera di Christina Elisabeth Herder
Precedenti posizioni note di Christina Elisabeth Herder
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| PCI BIOTECH HOLDING ASA | Direttore/Membro del Consiglio | 17/05/2015 | 25/05/2023 |
| Independent Dir/Board Member | 17/05/2015 | 25/05/2023 | |
| MEDIVIR AB | Corporate Officer/Principal | - | 01/12/2021 |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Amministratore Delegato | 01/01/2014 | 25/04/2017 |
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | 06/05/2010 | 01/01/2014 |
| ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
| ░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Formazione di Christina Elisabeth Herder
| Royal Institute of Technology | Doctorate Degree |
| University of Stockholm | Masters Business Admin |
Statistiche
Distribuzione geografica
| Svezia | 15 |
| Norvegia | 2 |
Posizioni
| Director/Board Member | 6 |
| Corporate Officer/Principal | 5 |
| Independent Dir/Board Member | 3 |
Settori
| Health Technology | 10 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 7 |
|---|---|
| PCI BIOTECH HOLDING ASA | Health Technology |
| MODUS THERAPEUTICS HOLDING AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| IDOGEN AB (PUBL) | Health Technology |
| ELICERA THERAPEUTICS AB | Health Technology |
| MEDIVIR AB | Health Technology |
| ZICCUM AB | Health Technology |
| Aziende private | 6 |
|---|---|
Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Health Technology |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
| Herder Consulting AB | |
| Glycovisc BioTech AB | |
| Medivir Personal AB |
